Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Soleno Therapeutics, Inc.'s quarterly P/E stands at 14.5x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 100.18 | 14.47 | 35.96 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.00 | 6.86 | 14.06 | 32.38 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.72 | 5.59 | 7.50 | 17.61 | 14.21 | 8.06 | 7.99 | 5.61 | 10.81 | 6.73 | 14.53 | 17.99 | 38.30 |
| — | -30.6% | -6.1% | +213.7% | +31.4% | +19.6% | -45.0% | -68.8% | -71.8% | -25.4% | +180.9% | +181.5% | +1034.3% | |
| P/FCF | 0.00 | 12.93 | 21.27 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | -1.11 | 6.85 | 38.36 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | -1.09 | — | 31.65 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Soleno Therapeutics, Inc.'s operating margin was 100.1% in Q4 2025, up 66.6 pp QoQ. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 37.9% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 98.3% | 97.9% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | 32.4% | 100.1% | 33.5% | -20.0% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | 11.0% | 47.3% | 39.4% | -14.4% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6.0% | 9.2% | 7.1% | -2.0% | -18.3% | -22.0% | -28.1% | -10.3% | -14.2% | -12.5% | -60.9% | -112.5% | -128.7% |
| — | +141.8% | +125.2% | +80.7% | -28.9% | -75.7% | +53.9% | +90.8% | +88.9% | +70.9% | -76.4% | -291.2% | -397.4% | |
| ROA | 4.7% | 7.5% | 5.6% | -1.4% | -13.5% | -17.8% | -25.5% | -9.2% | -12.2% | -9.3% | -23.0% | -33.6% | -36.3% |
| — | +141.8% | +121.9% | +84.3% | -10.2% | -92.8% | -10.9% | +72.5% | +66.3% | +50.7% | -29.0% | -98.2% | -147.7% | |
| ROIC | 15.6% | 21.7% | 7.1% | -2.3% | -16.6% | -20.7% | -27.1% | -10.7% | -39.5% | — | — | — | — |
| — | +205.3% | +126.1% | +78.3% | +58.0% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Soleno Therapeutics, Inc.'s Debt/EBITDA ratio is 0.0x, down from 0.1x last quarter — comfortably within a safe range. The current ratio has weakened 63.0% YoY to 5.80x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.22 | 0.23 | 0.22 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 | 0.01 |
| — | -97.2% | -50.4% | +20748.5% | +9292.8% | +8321.9% | -43.5% | -97.3% | -83.6% | -82.9% | +28.7% | +135.2% | -7.6% | |
| Debt / EBITDA | 0.04 | 0.03 | 0.12 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.80 | 5.80 | 16.08 | 15.13 | 19.64 | 15.68 | 17.26 | 29.24 | 11.23 | 14.89 | 1.85 | 2.33 | 1.18 |
| — | -63.0% | -6.8% | -48.3% | +74.8% | +5.3% | +832.4% | +1154.8% | +855.1% | +596.1% | -33.9% | -32.2% | -71.3% | |
| Quick Ratio | 5.55 | 5.55 | 15.88 | 15.01 | 19.64 | 15.68 | 17.26 | 29.24 | 11.23 | 14.89 | 1.85 | 2.33 | 1.18 |
| — | -64.6% | -8.0% | -48.6% | +74.8% | +5.3% | +832.4% | +1154.8% | +855.1% | +596.1% | -33.9% | -32.2% | -71.3% | |
| Interest Coverage | — | — | 15.90 | -4.74 | -33.61 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSoleno Therapeutics, Inc.'s current P/E is 100.2x. The average P/E over the last 2 quarters is 25.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Soleno Therapeutics, Inc.'s current operating margin is 32.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Soleno Therapeutics, Inc.'s business trajectory between earnings reports.